Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index; 6 of the 55 sources its claims cite were checked for support.

Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes

Open access

Abstract

Orforglipron (LY3502970) is a novel, orally available, nonpeptide glucagon-like peptide-1 receptor agonist (GLP-1 RA) designed to replicate the efficacy of injectable GLP-1 RAs for glycemic control and weight reduction while improving convenience and adherence. Preclinical studies have demonstrated potent receptor engagement, favorable pharmacokinetics, and central nervous system activity. Phase 1–3 clinical trials have shown significant reductions in glycated hemoglobin (HbA1c), fasting and postprandial glucose, body weight, and cardiovascular risk biomarkers, with an acceptable safety profile. This comprehensive review integrates pharmacological, clinical, and mechanistic evidence, critically evaluates the data, identifies knowledge gaps, and outlines future directions for orforglipron in the treatment of type 2 diabetes and obesity.

Overview

CoChat Summary

TL;DR

Orforglipron is an oral, nonpeptide, allosteric GLP-1 receptor agonist that produces clinically meaningful HbA1c and weight reductions in type 2 diabetes and obesity, with a safety profile dominated by dose-dependent gastrointestinal events. This comprehensive review integrates preclinical, Phase 1–3, mechanistic, and meta-analytic evidence while highlighting unresolved questions about long-term outcomes, comparative effectiveness, and understudied populations.

Key findings

  • Orforglipron is orally bioavailable (~30–40%), reaches peak plasma concentrations within 2–4 h, and supports once-daily dosing; food intake has minimal impact on exposure.
  • In Phase 2 T2D trials, once-daily orforglipron produced dose-dependent HbA1c reductions exceeding 1.5 percentage points at 26 weeks and mean body weight reductions of 7–10% at 26 weeks.
  • In ACHIEVE-1, early T2D patients had mean absolute HbA1c reductions of ~1.4–1.6% over 40 weeks without significant hypoglycemia; in ATTAIN, over 72 weeks, the highest dose yielded mean weight loss of 12–15% in non-diabetic participants and 10–12% in T2D populations.
  • Meta-analyses cited in the review report pooled weight reductions of 9–12% versus placebo at 26–72 weeks and weighted mean HbA1c reductions of 1.3–1.6% versus placebo; gastrointestinal adverse events were the most common, while hypoglycemia was rare and no pancreatitis, retinal detachment, or ischemic optic neuropathy signals were observed.

Methods

  • Design: comprehensive narrative review integrating preclinical pharmacology, Phase 1–3 clinical trials, mechanistic substudies, and published meta-analyses; no new primary data are reported.
  • Data/sample: healthy volunteers, participants with T2D, participants with obesity with or without diabetes, Japanese participants with T2D, and trial populations from ACHIEVE-1 and ATTAIN-1/ATTAIN-2.
  • Main analysis: qualitative synthesis of pharmacokinetic, pharmacodynamic, glycemic, weight-loss, safety, cardiovascular biomarker, hepatic, and renal data, with summary tables and cross-trial comparisons.

Limitations

  • Stated in the paper: most trials lasted only ~26–72 weeks, limiting assessment of long-term durability, late-emerging adverse events, and sustained cardiometabolic benefit; elderly patients, adolescents, individuals with severe obesity, and those with advanced renal or hepatic impairment were excluded or minimally represented; real-world effectiveness data are lacking; direct head-to-head comparisons and hard cardiovascular/renal outcome trials are absent.
  • Stated in the paper: mechanistic gaps remain, including the relative contributions of weight-dependent versus weight-independent glycemic effects, central appetite pathways, β-cell preservation, and the molecular basis of nonpeptide allosteric activation.
  • Evident from the text: as a narrative review, conclusions rely on cross-trial comparisons and surrogate biomarkers rather than primary comparative or long-term outcome data; no systematic search or formal quality appraisal is described.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3390/ijms27031409

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Chemical structure of orforglipron.
Figure 1 Chemical structure of orforglipron.CC BY · PubMed Central
Figure 2 Chemical (ball-and-stick) structure of orforglipron, dominated by interconnected aromatic and heteroaromatic rings forming a dense three-dimensional core. Black spheres represent carbon atoms; red spheres are oxygen atoms, green spheres represent fluorine (F) atoms, and white spheres are hydrogen atoms; nitrogen atoms (blue) are embedded within heterocycles and serve as key polar interaction points. Short aliphatic linkers connect aromatic domains, creating a balanced geometry that combines lipophilic planar regions with polar protrusions. The absence of long flexible chains or peptide-like backbones results in a relatively globular, non-extended shape, well suited for insertion into the transmembrane allosteric pocket of the GLP-1 Receptor.
Figure 2 Chemical (ball-and-stick) structure of orforglipron, dominated by interconnected aromatic and heteroaromatic rings forming a dense three-dimensional core. Black spheres represent carbon atoms; red spheres are oxygen atoms, green spheres represent fluorine (F) atoms, and white spheres are hydrogen atoms; nitrogen atoms (blue) are embedded within heterocycles and serve as key polar interaction points. Short aliphatic linkers connect aromatic domains, creating a balanced geometry that combines lipophilic planar regions with polar protrusions. The absence of long flexible chains or peptide-like backbones results in a relatively globular, non-extended shape, well suited for insertion into the transmembrane allosteric pocket of the GLP-1 Receptor.CC BY · PubMed Central

Verification

Claims the paper makes

1 Valid · 2 Not valid · 27 Not checked · 25 Own results and interpretations

27 more claims

Create a free account to see all 55 claims and to verify the 49 references still open.

See all claims — free account
  • It may state two separate claims as one. 22
  • The quote only partly states this claim. 1
  • Probably not a substantial claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 91 references

Research works printed but not linked: 3

  1. Jagarlapudi, 2025, Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes, N. Engl. J. Med., 393, 2276, 10.1056/nejmc2515117 · DOI · Paper page
  2. Nagaoka, 2025, Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes, N. Engl. J. Med., 393, 2276, 10.1056/nejmc2515117 · DOI · Paper page
  3. Xie, 2025, Orforglipron, an Oral GLP-1 Receptor Agonist, in Early Type 2 Diabetes, N. Engl. J. Med., 393, 2276, 10.1056/nejmc2515117 · DOI · Paper page

Cited by

See all 22

Metadata

Authors
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G.
Affiliations
  • City University of New York (US)
  • Casa di Cura “Clinica Montevergine”, 83013 Mercogliano, Italy
Corresponding author
Santulli, Gaetano
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2026-01-30
Volume
27
Issue
3
Pages
1409
ISSN
1422-0067 (ISSN-L)
OpenAlex
W7126191026
Cited by
22
References
91
Citations by year
2026: 22
FWCI
23.39
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Funders
  • National Institutes of Health (NIH): National Heart, Lung, and Blood Institute (R01-HL146691, R01-HL164772, R01-HL159062)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK123259, R01-DK033823)
  • American Heart Association (24IPA1268813)
  • AHA (AHA-23POST1026190, AHA-21POST836407, 26POST1563063, AHAPOST22915561, AHAPOST241195524)
  • NIH (T32-HL-172255)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
orforglipron, GLP-1 receptor agonists, oral GLP-1 receptor agonists, type 2 diabetes, obesity, glycemic control, weight loss, HbA1c, cardiovascular risk markers, pharmacokinetics, drug safety
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Administration, Oral, Animals, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity, Oxadiazoles, Fluorine Compounds

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes. https://app.cochat.ai/papers/10.3390/ijms27031409
The paper
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026). Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27031409

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.